Table 2.
Effect of tachykinin receptors antagonism on asthma outcomes
| Control | Treated | ||||
|---|---|---|---|---|---|
| Outcome | N | Mean(SD) | N | Mean(SD) | p |
| • AIRWAY RESPONSIVENESS: | |||||
| Log PC35 sGaw NKA mol/ml | |||||
| FK224 (NK-1R/NK-2R antagonist) | 10 | -6.04(0.18) | 10 | -6.19(0.23) | n.s. |
| Joos et al, 1996 | |||||
| PC20-AMP mg/ml | |||||
| SR 48968C (NK-1R/NK2R antagonist) | |||||
| Kraan et al, 2001 | 12 | 1.46(1.11) | 6 | 1.25(0.98) | n.s. |
| Log10PC20-NKA mol/ml | |||||
| MEN 11420 (NK-2R antagonist) | |||||
| Shelfhout et al, 2009 | 12 | -6.38(0.26) | 12 | -6.92(0.25) | 0.028 |
| AVE 5883 (NK-1R/NK-2R antagonist) | |||||
| Boot et al, 2007 | 19 | -6.40(0.12) | 19 | -6.74(0.12) | 0.004 |
| CS-003 (NK-1R/NK-2R/NK-3R antagonist) | |||||
| Schelfhout et al, 2006 | 15 | -5.92(0.83) | 15 | -6.99(0.66) | <0.05 |
| DNK 333 (NK-1R/NK-2R antagonist) | |||||
| Joos et al, 2004 | 18 | -5.60* | 18 | -6.8* | <0.001 |
| SR 48068 (NK-2R antagonist) | |||||
| Schoor et al, 1998 | 12 | -7.02(0.28) | 12 | -7.64(0.19) | 0.05 |
| • LUNG FUNCTION: | |||||
| FEV1 (% fall) | |||||
| AVE 5883 (NK-1R/NK-2R antagonist) | |||||
| Boot e tal, 2007 | 19 | 145.5(11.7) | 19 | 116.2(11.7) | 0.01 |
| SR 48968C (NK-1R/NK2R antagonist) | |||||
| Kraan e tal, 2001 | 12 | 81(4) | 6 | 78(3) | n.s. |
| FEV1 (L) | |||||
| CS-003 (NK-1R/NK-2R/NK-3R antagonist) | |||||
| Schelfhout e tal, 2006 | 15 | 3.34(0.62) | 15 | 3.25(0.71) | n.s. |
| FK224 (NK-1R/NK-2R antagonist) | |||||
| Joos e tal, 1996 | 10 | 3.66 × 10-3(0.25) | 10 | 3.67 × 10-3 (0.21) | n.s. |
| • AIRWAY INFLAMMATION: | |||||
| Eosinophils % | |||||
| AVE 5883 (NK-1R/NK-2R antagonist) | |||||
| Boot e tal, 2007 | 19 | 4.86(1.75) | 19 | 3.33(1.58) | n.s. |
| eNO ppb | |||||
| AVE 5883 (NK-1R/NK-2R antagonist) | |||||
| Boot e tal, 2007 | 19 | 37.64(6.40) | 19 | 43.44(6.57) | 0.32 |
* 95% Confidence Interval for the difference in Log10PC20-NK, 0.841-1.616.
SP - substance P; eNO - exhaled nitric oxide; n.s. - reported as not significant.